Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH

BACKGROUND: Patients with metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis are at risk for progression to cirrhosis and clinical outcomes, but can also experience fibrosis regression. The aim of this study was to compare risk stratification by the Enhanced Liver Fibrosis (ELF) Test to histological staging to assess patients at risk of disease progression and those likely to experience histological regression. METHODS: Using pooled data from 6 large placebo-controlled trials of 2710 patients with advanced fibrosis due to MASH, 4 analyses of ELF and fibrosis stage were performed to evaluate the association with the following events: (1) liver-related clinical outcomes; (2) progression from bridging fibrosis to cirrhosis; (3) regression from bridging fibrosis; (4) regression from cirrhosis. Significance was assessed by interval likelihood ratio (iLR), Cox proportional hazard ratio (HR), and area under the receiver operator characteristic curve (AUROC). RESULTS: In 2304 participants (17.8 mo mean follow-up), there was a progressive rise in liver-related outcome risk with increasing baseline ELF score [<9.00 (0%), ≥9.00 to <9.80 (2%), ≥9.80 to <11.30 (4%), ≥11.30 to <12.80 (13%), ≥12.80 (40%)]. In 1414 patients with bridging fibrosis, increasing baseline ELF scores were associated with a higher risk of progression to cirrhosis [<9.80 (9%), ≥9.80 to <11.30 (18%), ≥11.30 (45%)] and a lower likelihood of histological regression. In 1690 patients with cirrhosis, increasing baseline ELF scores were associated with a lower likelihood of histological regression [<9.80 (33%), ≥9.80 to <11.30 (16%), ≥11.30 (6%)]. In all analyses, the ELF Test provided more detailed information than histology. CONCLUSIONS: The ELF Test adds risk strata that are significantly different from fibrosis staging for the prediction of clinical events and histological changes, thereby improving risk stratification.

Authors

Institutions

Publication Details

Journal
Hepatology Communications
Published
2026-04-24
DOI
https://doi.org/10.1097/hc9.0000000000000931
Citations
1
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
19.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH

M. Gee, Rachel Fonstad, Keyur Patel, Edward B. De Vol et al.
1 citations
Hepatology Communications
Liver Disease Diagnosis and Treatment
19.42
article

Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH

M. Gee, Rachel Fonstad, Keyur Patel, Edward B. De Vol, Chadwick Brown, Jordan J. Feld, Arun J. Sanyal
article en
1 citations

Abstract

BACKGROUND: Patients with metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis are at risk for progression to cirrhosis and clinical outcomes, but can also experience fibrosis regression. The aim of this study was to compare risk stratification by the Enhanced Liver Fibrosis (ELF) Test to histological staging to assess patients at risk of disease progression and those likely to experience histological regression. METHODS: Using pooled data from 6 large placebo-controlled trials of 2710 patients with advanced fibrosis due to MASH, 4 analyses of ELF and fibrosis stage were performed to evaluate the association with the following events: (1) liver-related clinical outcomes; (2) progression from bridging fibrosis to cirrhosis; (3) regression from bridging fibrosis; (4) regression from cirrhosis. Significance was assessed by interval likelihood ratio (iLR), Cox proportional hazard ratio (HR), and area under the receiver operator characteristic curve (AUROC). RESULTS: In 2304 participants (17.8 mo mean follow-up), there was a progressive rise in liver-related outcome risk with increasing baseline ELF score [<9.00 (0%), ≥9.00 to <9.80 (2%), ≥9.80 to <11.30 (4%), ≥11.30 to <12.80 (13%), ≥12.80 (40%)]. In 1414 patients with bridging fibrosis, increasing baseline ELF scores were associated with a higher risk of progression to cirrhosis [<9.80 (9%), ≥9.80 to <11.30 (18%), ≥11.30 (45%)] and a lower likelihood of histological regression. In 1690 patients with cirrhosis, increasing baseline ELF scores were associated with a lower likelihood of histological regression [<9.80 (33%), ≥9.80 to <11.30 (16%), ≥11.30 (6%)]. In all analyses, the ELF Test provided more detailed information than histology. CONCLUSIONS: The ELF Test adds risk strata that are significantly different from fibrosis staging for the prediction of clinical events and histological changes, thereby improving risk stratification.

Hepatology CommunicationsVol. 10(5)
University Health Network (CA), Virginia Commonwealth University (US), University of Toronto (CA), Siemens Healthcare (United States) (US)
Gilead Sciences
Good health and well-being
Openalex Percentile: Top 1%
Liver Disease Diagnosis and Treatment
19.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.